Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 15,000 shares of Cytokinetics stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $61.93, for a total value of $928,950.00. Following the completion of the transaction, the executive vice president owned 50,440 shares of the company’s stock, valued at approximately $3,123,749.20. The trade was a 22.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Andrew Callos also recently made the following trade(s):

• On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total value of $55,020.60.
• On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $60.28, for a total transaction of $904,200.00.
• On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total transaction of $112,590.76.
• On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The stock was sold at an average price of $62.44, for a total transaction of $112,953.96.
• On Monday, December 8th, Andrew Callos sold 1,042 shares of Cytokinetics stock. The stock was sold at an average price of $65.96, for a total transaction of $68,730.32.
• On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The shares were sold at an average price of $65.95, for a total transaction of $3,461,451.70.

Cytokinetics Stock Up 3.5%

Shares of NASDAQ:CYTK opened at $62.34 on Friday. The company has a market cap of $7.62 billion, a PE ratio of -9.91 and a beta of 0.54. Cytokinetics, Incorporated has a fifty-two week low of $29.31 and a fifty-two week high of $70.98. The firm has a 50-day simple moving average of $63.35 and a 200 day simple moving average of $55.50.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analyst estimates of $6.05 million. The business’s revenue was up 318.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.36) earnings per share. As a group, research analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytokinetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYTK. UMB Bank n.a. increased its position in shares of Cytokinetics by 10.6% during the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 169 shares during the period. CIBC Private Wealth Group LLC boosted its stake in Cytokinetics by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 261 shares in the last quarter. Fifth Third Bancorp grew its holdings in Cytokinetics by 32.3% during the third quarter. Fifth Third Bancorp now owns 1,072 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 262 shares during the period. Danske Bank A S raised its position in Cytokinetics by 23.1% in the fourth quarter. Danske Bank A S now owns 1,600 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 300 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its holdings in Cytokinetics by 1.2% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 24,415 shares of the biopharmaceutical company’s stock valued at $1,551,000 after acquiring an additional 300 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $95.00 price target on shares of Cytokinetics in a report on Wednesday, January 21st. The Goldman Sachs Group set a $95.00 price objective on shares of Cytokinetics and gave the company a “buy” rating in a research report on Thursday, December 18th. Truist Financial upped their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays started coverage on shares of Cytokinetics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price target on the stock. Finally, Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Seventeen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and an average target price of $87.42.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.